Berobenatide vs Semaglutide (Wegovy tablets)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

Berobenatide

Developed by Pfizer

Phase 3 in Obesitypeptide
Partial signal

NCT06712836 · Phase 2 · completed

The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2027 · NCT07508241 (registry estimate)

Reported efficacy

Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)

Result source: NCT06712836

Semaglutide (Wegovy tablets)

Marketed by Novo Nordisk

Approved in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07225816 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBerobenatideSemaglutide (Wegovy tablets)
Body weight, % change—Trial running · NCT07311850-14.9% vs -1.5%−13.4 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -15.8% vs -2.2% 50 mg once daily · wk 68 · n 317 · Phase 3 · primary NCT05035095
  • -14.4% vs -2.5% 25 mg once daily · wk 64 · n 192 · Phase 3 · primary NCT05564117
Weight loss of 5% or more—Trial running · NCT07311850—Not posted · NCT05890976
Weight loss of 10% or more—Trial running · NCT07311850—Not posted · NCT05890976
Waist circumference, change (cm)—Trial running · NCT07311850-11.2 vs -1.4−9.8 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -13.4 vs -2.8 50 mg once daily · wk 68 · n 317 · Phase 3 · secondary NCT05035095
  • -12.9 vs -3.1 25 mg once daily · wk 64 · n 191 · Phase 3 · secondary NCT05564117

Body weight, % change

Berobenatide
—Trial running · NCT07311850
Semaglutide (Wegovy tablets)
-14.9% vs -1.5%−13.4 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -15.8% vs -2.2% 50 mg once daily · wk 68 · n 317 · Phase 3 · primary NCT05035095
  • -14.4% vs -2.5% 25 mg once daily · wk 64 · n 192 · Phase 3 · primary NCT05564117

Weight loss of 5% or more

Berobenatide
—Trial running · NCT07311850
Semaglutide (Wegovy tablets)
—Not posted · NCT05890976

Weight loss of 10% or more

Berobenatide
—Trial running · NCT07311850
Semaglutide (Wegovy tablets)
—Not posted · NCT05890976

Waist circumference, change (cm)

Berobenatide
—Trial running · NCT07311850
Semaglutide (Wegovy tablets)
-11.2 vs -1.4−9.8 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -13.4 vs -2.8 50 mg once daily · wk 68 · n 317 · Phase 3 · secondary NCT05035095
  • -12.9 vs -3.1 25 mg once daily · wk 64 · n 191 · Phase 3 · secondary NCT05564117
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Berobenatide
Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). NCT06712836 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Berobenatide: 0 of 4 rows · Semaglutide (Wegovy tablets): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSemaglutide (Wegovy tablets)
Dropout rate
4.4%25 mg once dailya
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
3%50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
4.2%50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—25 mg once dailya
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
—50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Serious AEs
3.9%25 mg once dailya
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
6%50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
9.6%50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
25 mg once dailya
nausea 46.6% (placebo 18.6%)
vomiting 30.9% (placebo 5.9%)
nasopharyngitis 21.1% (placebo 26.5%)
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
50 mg
covid-19 30.6% (placebo 33.3%)
nausea 25.4% (placebo 7.6%)
constipation 20.9% (placebo 9.1%)
NCT05132088 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 51.8% (placebo 15.3%)
covid-19 35.6% (placebo 34.5%)
constipation 27.5% (placebo 15%)
NCT05035095 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Wegovy tablets)

Weight -14.9% (n=127) vs -1.5% (n=64) placebo @ 68wk50 mg
percent change · % of baseline
NCT05132088 · Phase 3 · registry result, not featured evidence
show 2 more results
-15.8% (n=317) vs -2.2% (n=295) placebo @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
-14.4% (n=192) vs -2.5% (n=90) placebo @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 84.3% (n=127) vs 17.2% (n=64) placebo @ 68wk50 mg
event count · % of participants
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
show 2 more results
84.9% (n=317) vs 25.8% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 269 Participants as posted
79.2% (n=192) vs 31.1% (n=90) placebo @ 64wk*25 mg once daily
Yes
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to % from 152 Participants as posted
Weight Loss 10% 65.4% (n=127) vs 9.4% (n=64) placebo @ 68wk50 mg
event count · % of participants
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
show 2 more results
69.4% (n=317) vs 11.9% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 220 Participants as posted
63% (n=192) vs 14.4% (n=90) placebo @ 64wk*25 mg once daily
Yes
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to % from 121 Participants as posted
Weight Loss 15% 47.2% (n=127) vs 0% (n=64) placebo @ 68wk50 mg
event count · % of participants
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 60 Participants as posted
show 2 more results
53.6% (n=317) vs 5.8% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 170 Participants as posted
50% (n=192) vs 5.6% (n=90) placebo @ 64wk*25 mg once daily
Yes
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
Weight Loss 20% 32.3% (n=127) vs 0% (n=64) placebo @ 68wk50 mg
event count · % of participants
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
show 2 more results
33.8% (n=317) vs 2.7% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
29.7% (n=192) vs 3.3% (n=90) placebo @ 64wk*25 mg once daily
Yes
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted
IWQOL-Lite-CT Physical Function 7.6 vs 1.9 placebo score @ 68wk50 mg
absolute change · score
NCT05132088 · Phase 3 · registry result, not featured evidence
show 2 more results
14.5 vs 5 placebo score @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
16.8 vs 8.3 placebo score @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence
IWQOL-Lite-CT Physical Function 50% (n=298) vs 31.3% (n=278) placebo @ 68wk50 mg once daily
responder rate · % of participants
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted
show 1 more result
55.3% (n=188) vs 34.8% (n=89) placebo @ 64wk*25 mg once daily
Yes
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted
Weight -16.1 vs -2.4 placebo kg @ 68wk50 mg once daily
absolute change · kg
NCT05035095 · Phase 3 · registry result, not featured evidence
show 1 more result
-15 vs -2.3 placebo kg @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence
BMI -4.89 vs -0.47 placebo kg @ 68wk50 mg
absolute change · kg
NCT05132088 · Phase 3 · registry result, not featured evidence
show 2 more results
-5.9 vs -0.9 placebo kg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
-5.3 vs -0.9 placebo kg @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence
Waist Circumference Change -11.2 vs -1.4 placebo cm @ 68wk50 mg
absolute change · cm
NCT05132088 · Phase 3 · registry result, not featured evidence
show 2 more results
-13.4 vs -2.8 placebo cm @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
-12.9 vs -3.1 placebo cm @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence
SBP -11 vs -2 placebo mmHg @ 68wk50 mg
absolute change · mmHg
NCT05132088 · Phase 3 · registry result, not featured evidence
show 2 more results
-7 vs -1 placebo mmHg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
-7 vs -5 placebo mmHg @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence
DBP -6 vs -1 placebo mmHg @ 68wk50 mg
absolute change · mmHg
NCT05132088 · Phase 3 · registry result, not featured evidence
show 2 more results
-2 vs -1 placebo mmHg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
-3 vs -2 placebo mmHg @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Berobenatide's landscape · Semaglutide (Wegovy tablets)'s landscape